bstract. We have evaluated the hypolipidemic effects of mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis in 13 patients with heterozygous familial hypercholesterolemia (FH 
Introduction
Patients with heterozygous familial hypercholesterolemia (FH)' constitute a group at high risk for the premature development of atherosclerosis (1) (2) (3) (4) (5) . This disorder, which is inherited as an autosomal dominant trait (6) , is biochemically heterogeneous and results from abnormalities in receptor-mediated uptake and metabolism of low density lipoprotein (LDL) by cells (7) .
Kinetic studies of '251-labeled LDL in patients with heterozygous FH have indicated that the reduced number of high affinity LDL receptors expressed on their cells results in a reduced fractional rate of catabolism of LDL from plasma (8) (9) (10) and is associated with lifelong hypercholesterolemia.
Because oftheir strong predilection for premature coronary artery disease, patients with heterozygous FH constitute a population in whom long-term hypocholesterolemic therapy to reduce elevated levels of LDL cholesterol is most clearly indicated. Current therapy of this disorder consists of dietary restriction of saturated fats and cholesterol and the use of pharmaceutical agents (11) (12) (13) (14) , or less commonly, surgical bypass of the distal ileum (15) . The bile acid sequestrants, cholestyramine or colestipol, or nicotinic acid, are considered the agents of choice for single drug therapy (16) (17) (18) . The former agents, like distal ileal bypass (19) , increase fecal bile acid excretion and stimulate compensatory increases in the hepatic conversion of cholesterol to bile acids. This in turn promotes further compensatory increases in de novo cholesterol biosynthesis and in the number of high affinity LDL receptors present on hepatocyte membranes (20) ; the latter increase 1 . Abbreviations used in this paper: CPK, creatine phosphokinase; FH, familial hypercholesterolemia; HMG-COA, 3-hydroxy-3-methylglutaryl coenzyme A. results in an enhanced rate of receptor-mediated LDL catabolism (21) and a fall in the concentrations of this lipoprotein in plasma.
The recent development of two specific competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, 3- hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase, compactin (21) (22) (23) (24) (25) and mevinolin (26) (27) (28) , has 
Methods
Subjects. 13 adult patients with severe type II hypercholesterolemia, in whom prior hypolipidemic therapy (11) (12) (13) (14) had failed to lower serum cholesterol values below 300 mg/dl, participated in the study (Table  I) In initial studies five patients were sequentially maintained on doses of 5, 10, or 20 mg mevinolin twice daily for a period of 6 wk on each dose. Plasma cholesterol values in these patients were as follows: base line, 444±21 mg/dl, (mean±SEM); 5 mg mevinolin twice daily, 392±20 mg/dl after 2 wk, 363±21 mg/dl after 4 wk, 355±16 mg/dl after 6 wk; 10 mg mevinolin twice daily, 336±20 mg/dl after 2 wk, 325±16 mg/dl after 4 wk, and 324±14 mg/dl after 6 wk; and on 20 mg of mevinolin twice daily, 317±14 mg/dl after 2 wk, 296±17 mg/dl after 4 wk, and 309±14 mg/dl after 6 wk. Statistical analysis (one-way analysis of variance with repeated measures) indicated a significant (P < 0.05) further decrease in total cholesterol between wk 2 and 4 on the 5 mg twice daily dosage of mevinolin but no statistical significance between the values at 4 and 6 wk. For all other mevinolin doses (10, 20 , and 40 mg twice daily) the lipid values after 2 wk on each dose were not statistically different from those at 4 and 6 wk.
This analysis also indicates that the statistically significant changes in total and LDL cholesterol that occurred in response to increasing doses of mevinolin (up to 20 mg twice daily) are attributable to the higher dosage rather than a carryover effect from previous administration of the lower dose. Based on these preliminary studies, which indicated that stable lipid values are attained in 4 wk or less on a given dose of mevinolin, changes to a higher dose were made after 4 wk on each dose of mevinolin in the remainder of the study patients. The data reported in this paper therefore represent values obtained after a 4-wk period on each dose of mevinolin. Blood samples for hematologic (white blood cell count, hemoglobin, hematocrit, and platelet count) 
Results
Changes in the concentrations of plasma total and LDL cholesterol in the 13 patients with heterozygous FH during sequential therapy with increasing doses of mevinolin are shown in Fig. 1 and 2 . In each figure the results represent single-point determinations on each patient after 4 wk on a given dose of mevinolin. Total plasma cholesterol concentrations fell from a base-line value of 450±14 (mean±SEM) to 373±13 mg/dl after 4 wk on 5 mg twice daily of mevinolin (P < 0.05), 344±15 mg/dl on 10 mg twice daily (P < 0.05 vs. the 5 mg twice daily dose), 313±15 mg/dl on 20 mg of mevinolin twice daily (P<0.05 vs. the 10 mg twice daily dose), and 300±15 mg/dl after 4 wk on 40 mg twice daily of mevinolin. The latter two values are not significantly different. Changes in the concentrations of LDL cholesterol in the 13 patients during sequential therapy with mevinolin paralleled those for total cholesterol ( Although the individual responses show considerable variation, the overall trend was for a progressive decrease in the concentrations of both total and LDL cholesterol at doses of mevinolin up to 20 mg twice daily, at which point a plateau was reached (Fig. 3) . As illustrated in Fig. 3 and Table II , plasma triglycerides fell slightly on the lower doses of mevinolin (a 6% decrease on the 5 mg twice daily dosage and 11% fall on the 10 mg twice daily regimen) but were significantly lower on the 20 or 40 mg twice daily regimens. Plasma triglyceride concentrations on the latter doses of mevinolin decreased by 30.7 and 34.3%, respectively (P < 0.05 vs. base line). Concentrations of HDL cholesterol remained stable throughout the period of study and were not influenced by mevinolin (Fig. 3 , Table II ). Mevinolin was uniformly well tolerated and no patient was withdrawn from the study. Two patients reported subjective but transient changes while taking mevinolin. These were an increased frequency of headaches in one patient (case 7) and insomnia in the second (case 9), both at a time when they were receiving 40 mg of mevinolin twice daily. In both cases these symptoms have resolved and the patients remain on therapy (20 
Discussion
The hypocholesterolemic effects of two specific competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis HMG-COA reductase, compactin (23-25) and mevinolin (27) (28) (29) , have been reported in normal subjects and in patients with heterozygous FH, but the dose-response relationships have only been examined in the former (28) . In a multicenter trial, Tobert et al. (28) examined the hypolipidemic effects of mevinolin given in doses of 6.25, 12.5, 25, and 50 mg twice daily to normal male volunteers. Concentrations of LDL cholesterol fell by 35-45% in all groups and despite a slightly larger decrease on the 50 mg twice daily dosage, differences between groups were not significant. These results in normal subjects differ from those of the present study in patients with heterozygous FH in whom significantly greater decreases in the concentrations of total and LDL cholesterol were found on the 5, 10, and 20 mg twice daily doses of mevinolin. Concentrations of LDL cholesterol were reduced by 35% on 20 mg of mevinolin twice daily, at which dose a plateau effect was observed, and increases in mevinolin dose above this (to 40 mg twice daily) resulted in insignificant further changes (mean 37.7% below base line).
The overall magnitude of lipid lowering reported in the present study with optimal doses of mevinolin is slightly greater than noted in previous studies in which fixed doses of mevinolin or compactin have been administered to patients with heterozygous FH. Mabuchi et al. (24) per day on diet only vs. 18.4 mg/kg per day on mevinolin), in the patients as a whole it fell modestly in five of the six individual subjects but increased appreciably in the sixth. These results indicate that the observed decrease in LDL cholesterol levels in patients with heterozygous FH treated with 20 mg of mevinolin twice daily is mediated primarily by an increased fractional rate of LDL catabolism, but that some reduction in LDL synthesis may occur concurrently. Indirect support for an inhibitory effect of mevinolin on LDL and very low density lipoprotein synthesis is suggested by the findings that a significant fall in plasma triglyceride concentrations occurred in patients receiving both the 20 and 40 mg twice daily doses of mevinolin. Such an effect was not observed at lower doses of mevinolin and it is tempting to speculate that the observed decreases in LDL on these doses (5 and 10 mg twice daily) were mediated exclusively by increases in the rate of receptor-mediated LDL catabolism, whereas some concurrent reduction in LDL synthesis was apparent on the two higher doses.
The hypocholesterolemic effects of mevinolin (and compactin) are based on their ability to competitively inhibit hepatic HMG-COA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and thereby reduce the rates of formation of mevalonic acid from HMG-COA and the de novo biosynthesis of cholesterol (32) . The latter action is believed to transiently reduce the cellular cholesterol pool and result in compensatory increases in the number of high affinity LDL receptors on the cell surface (20) with a concurrent stimulation in the rate of receptor-mediated LDL catabolism (20, 29) . This effect is similar to that which occurs in the liver when the entero-hepatic circulation of bile acids is interrupted either by oral administration of bile acid sequestrants, e.g., colestipol or cholestyramine (20, 21, 33) , or by surgical bypass of the distal ileum (15) , but the mechanisms differ. In the former situation mevinolin directly reduces the rate of cholesterol biosynthesis, whereas in the latter case depletion of the bile salt pool promotes compensatory increases in the conversion of cholesterol to bile acids and indirectly increases the rate of cellular cholesterol efflux. In patients with heterozygous FH, the ability of mevinolin and bile salt depletion to independently (21, 29) stimulate the production of more high affinity LDL receptors on hepatocytes affords a physiologically attractive and clinically effective means by which elevated LDL levels can be substantially reduced.
In addition to its role as a precursor of cholesterol, mevalonic acid is also an obligatory precursor (32) for the formation of ubiquinone (34) , dolichol (35) , and isopentenyl adenine (36) (24) . In this study, concentrations of total and LDL cholesterol fell by 32 and 29%, respectively, but serum concentrations of ubiquinone were unchanged.
Short-term side effects during treatment with mevinolin have been minimal and all the patients reported in this study remain on therapy. Laboratory changes have been limited to transient increases in alkaline phosphatase in three patients and to a modest but sustained increase in a fourth. Previously reported side effects with mevinolin (27-29) and compactin (23-25) have also been minimal. Mabuchi et al. (24) reported an insignificant increase in the overall levels of CPK in seven Japanese patients treated with compactin at a dose of 30-60 mg/d, but similar changes were not reported in a subsequent study with 10 patients treated with 90 mg of compactin/d (25) . Tobert et al. (28) noted increased levels of CPK (two patients) and SGOT (two patients) in a group of 59 normal male subjects given mevinolin for a period of 1 mo. These results, along with those of the present study, indicate that mevinolin is well tolerated at clinically effective doses and that short-term side effects are minimal at doses of up to 1.5 mg/ kg per day. Nevertheless, until more information on the longterm safety of mevinolin in humans is available, it would seem prudent to restrict its use to selected adult patients with refractory hypercholesterolemia in whom the potential benefit from effective hypolipidemic therapy appears greatest.
If long-term safety can be satisfactorily established, specific inhibitors of HMG-COA reductase used alone or with either a bile acid sequestrant (29, 37), distal ileal bypass (38), or nicotinic acid offer considerable promise in the therapy of patients with heterozygous FH and possibly in patients with other hereditary disorders (e.g., familial combined hyperlipidemia) that are associated with elevated levels of LDL cholesterol. The long-term use of such regimens affords the potential for preventing (39) or even reversing the premature development of atherosclerosis that occurs so frequently in this high risk group of patients.
